Konstas A G P

Quaranta L, Katsanos A, Riva I, Dastiridou A, Oddone F, Roberti G et al.

This study found most new normal tension glaucoma patients have highest eye pressure at night. However, 24-hour eye pressure or ocular perfusion pressure didn't correlate with visual field damage.

Konstas A G P, Quaranta L, Yan D B, Mikropoulos D G, Riva I, Gill N K et al.

This study compared two glaucoma fixed combinations, finding dorzolamide/timolol provided superior 24-hour IOP reduction compared to brimonidine/timolol in primary open-angle glaucoma, offering better pressure control.

Konstas A G P, Mikropoulos D G, Embeslidis T A, Dimopoulos A T, Papanastasiou A, Haidich A-B et al.

This study found travoprost/timolol fixed combination provided superior 24-hour IOP control, including lower mean and peak pressures, compared to latanoprost/timolol in exfoliative glaucoma, offering a potentially more effective treatment option.

Quaranta L, Konstas A G P, Rossetti L, Garcia-Feijoo J, O'Brien C, Nasr M B et al.

This study found untreated nighttime supine IOPs (Perkins) were not significantly higher than daytime sitting IOPs (Goldmann), but daytime readings don't consistently predict highest nighttime pressures, highlighting potential missed peaks.

Konstas A G P, Mikropoulos D, Haidich A-B, Ntampos K S, Stewart W C

This study found travoprost/timolol fixed combination significantly lowered 24-hour intraocular pressure and fluctuation more than travoprost alone in glaucoma patients, offering superior IOP control.

Konstas A G P, Irkec M T, Teus M A, Cvenkel B, Astakhov Y S, Sharpe E D et al.

This study found higher mean IOP and thinner corneas significantly increased glaucoma progression risk in OHT patients, highlighting the importance of IOP control and corneal thickness assessment.

Konstas A G P, Mikropoulos D, Dimopoulos A T, Moumtzis G, Nelson L A, Stewart W C

Adding dorzolamide/timolol to latanoprost monotherapy provided the greatest 24-hour IOP reduction compared to switching to fixed combinations, offering a superior strategy for glaucoma patients needing enhanced pressure control.

Konstas A G P, Katsimpris I E, Kaltsos K, Georgiadou I, Kordelou A, Nelson L A et al.

This study found that brimonidine/timolol fixed combination and its unfixed components offer equivalent, significant 24-hour IOP reduction in glaucoma/ocular hypertension patients, simplifying treatment without compromising efficacy.

Quaranta L, Pizzolante T, Riva I, Haidich A-B, Konstas A G P, Stewart W C

In normal-tension glaucoma, bimatoprost and latanoprost similarly lower 24-hour IOP. Latanoprost slightly improved ocular perfusion pressure, but both drugs yielded comparable overall perfusion and IOP reduction, offering similar clinical efficacy.

Konstas A G P, Holló G, Irkec M, Tsironi S, Durukan I, Goldenfeld M et al.

This study compared bimatoprost and latanoprost for exfoliative glaucoma; bimatoprost provided superior diurnal IOP reduction and target attainment, offering better disease control despite more side effects.

Damji K F, Konstas A G P, Liebmann J M, Hodge W G, Ziakas N G, Giannikakis S et al.

Cataract surgery lowers eye pressure more significantly in patients with exfoliation syndrome, especially those with glaucoma, an effect lasting at least two years.

Konstas A G P, Kozobolis V P, Lallos N, Christodoulakis E, Stewart J A, Stewart W C

This study compared two glaucoma fixed-combination drugs, finding similar daytime IOP reduction but different side effects, guiding treatment choices for patients.

Konstas A G P, Mylopoulos N, Karabatsas C H, Kozobolis V P, Diafas S, Papapanos P et al.

This study found latanoprost provided better 8 AM intraocular pressure reduction and more stable diurnal pressure than timolol in exfoliation glaucoma, suggesting its potential for superior early-morning control.

Koliakos G G, Konstas A G P, Schlötzer-Schrehardt U, Hollo G, Mitova D, Kovatchev D et al.

This study found increased Endothelin-1 in aqueous humor of exfoliation syndrome patients, suggesting its role in XFS pathobiology, potentially impacting its progressive iris vasculopathy and glaucoma risk.

Konstas A G P, Kozobolis V P, Tersis I, Leech J, Stewart W C

This study found timolol/dorzolamide and latanoprost similarly lowered IOP in exfoliation glaucoma. Both were effective, but latanoprost was preferred due to once-daily dosing and fewer side effects.